NIKI
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -4.20 | $0 | -$535,260 |
| 2025 Q3 | -8.50 | $0 | — |
| 2025 Q2 | -6.20 | $0 | — |
| 2024 Q4 | -14.60 | $0 | $89,730 |
| 2024 Q2 | -49.50 | $0 | -$1M |
| 2023 Q4 | 51.00 | $0 | -$2M |
| 2023 Q2 | -142.50 | $431,378 | -$6M |
| 2022 Q4 | -221.60 | $768,427 | -$5M |